Viatris Inc (VTRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1086)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Nächster Verdiensttermin

Neueste SEC-Einreichungen

VTRS's Discussions on Twitter

Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VTRS Viatris Inc	16.52	19.08B	14.57B	-296.50M	1.64B	-0.259
TAK Takeda Pharmaceutical Co Adr	18.25	58.50B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.79	42.84B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.19	40.68B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.67	30.40B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	502.79	21.36B	3.17B	1.29B	1.01B	27.09

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-09	Hochstufung	UBS	Neutral → Buy
2026-01-16	Hochstufung	Argus	Hold → Buy
2025-12-09	Eingeleitet	Barclays	Overweight
2025-10-15	Eingeleitet	Truist	Buy
2025-06-06	Eingeleitet	Goldman	Neutral
2024-07-19	Fortgesetzt	Jefferies	Buy
2023-10-23	Herabstufung	BofA Securities	Neutral → Underperform
2023-06-23	Herabstufung	Barclays	Equal Weight → Underweight
2023-04-24	Herabstufung	Barclays	Overweight → Equal Weight
2023-02-17	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Hochstufung	Jefferies	Hold → Buy
2022-11-10	Hochstufung	UBS	Sell → Neutral
2022-11-08	Hochstufung	Piper Sandler	Underweight → Neutral
2022-10-21	Fortgesetzt	Jefferies	Hold
2022-06-14	Eingeleitet	UBS	Sell
2022-05-10	Herabstufung	Piper Sandler	Neutral → Underweight
2022-03-01	Herabstufung	BofA Securities	Buy → Neutral
2022-03-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-06-15	Eingeleitet	Citigroup	Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2021-03-08	Herabstufung	Goldman	Buy → Neutral
2021-03-02	Herabstufung	JP Morgan	Overweight → Neutral
2021-02-26	Herabstufung	Wolfe Research	Outperform → Peer Perform
2021-01-05	Eingeleitet	Argus	Hold
2020-12-14	Eingeleitet	Bernstein	Mkt Perform

Alle ansehen

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Finanzdaten der Viatris Inc-Aktie (VTRS)

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo

Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan

Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo

Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews

Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune

Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune

Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune

Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch

Viatris Inc. stock rises Monday, outperforms market - MarketWatch

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance

Viatris Inc. (VTRS) Stock Analysis: Exploring Its 13% Upside Potential And Dividend Appeal - DirectorsTalk Interviews

Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough? - Yahoo Finance

Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overv - GuruFocus

Viatris Inc. stock falls Friday, underperforms market - MarketWatch

Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score - GuruFocus

Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch

Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.36% Potential Upside Amidst Mixed Financial Signals - DirectorsTalk Interviews

Viatris' China Policy Concerns Overstated, UBS Says - Moomoo

Barclays Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $22 - Moomoo

Viatris Inc. (VTRS) Stock Analysis: Healthcare Giant with a 13.99% Upside and Strategic Collaborations - DirectorsTalk Interviews

5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - Yahoo Finance

Viatris Inc. stock rises Friday, outperforms market - MarketWatch

Viatris Inc (VTRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com

Viatris Inc. (VTRS) Stock Price, News, Quote & History - Yahoo! Finance Canada

Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance

Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch

Davis Selected Advisers (VTRS) discloses 75.2M-share, 6.5% stake in Viatris Inc - Stock Titan

ETFs Investing in Viatris, Inc. Stocks - TradingView

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - TradingView

Harrow adds TYRVAYA's global rights to dry eye portfolio - Glance by Eyes On Eyecare

Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run - Sahm

Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash - TradingView

Viatris Inc. (VTRS) Stock Analysis: Unveiling a 12.6% Potential Upside Amidst Strong Cash Flow - DirectorsTalk Interviews

Why Viatris (VTRS) Is Down 6.4% After Boosting Guidance And Completing A $1.15 Billion Buyback - simplywall.st

Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program - finance.yahoo.com

Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval - Yahoo Finance

Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress - Yahoo Finance

Viatris Inc. (VTRS) Stock Forecasts - Yahoo! Finance Canada

Viatris (VTRS) Raises 2026 Guidance, Is The 11% Gap Below Fair Value Enough? - Yahoo Finance

Viatris (VTRS) Stock Looks Stuck Between Higher Guidance And Wider Losses - Sahm

Viatris Inc. (US92556V1061.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada

Viatris Inc. Stock Sheds 7.7%, Underperforms Market - webull.com

Viatris Earnings: Good Performance in Key Regions and Outlook Increase Make for a Solid Quarter - Morningstar

Harrow Enters Agreement to Acquire Tyrvaya Dry Eye Treatment From Viatris Inc. - VisionMonday.com

Viatris Inc. Stock 12‑Month Price Target Raised to $18.71, Implies 6% Upside - TradingView

Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ... - Yahoo Finance

Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overv - GuruFocus

Viatris Inc. stock falls Thursday, underperforms market - MarketWatch

Viatris Inc Q2 2026: Revenue $3.76B, EPS $(0.10) — 10-Q Summary - TradingView

Finanzdaten der Viatris Inc-Aktie (VTRS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie VTRS